

**Supplemental Digital Content 5: Proportion of Patients Showing Mean Changes in Area of Lesion and CNV at Baseline and Month 12 (Full analysis set\*) (modified last observation carried forward)**

	Baseline		Month 12	
	Mean (SD) lesion area, mm <sup>2</sup>	Mean (SD) CNV area, mm <sup>2</sup>	Mean (SD) lesion area, mm <sup>2</sup>	Mean (SD) CNV area, mm <sup>2</sup>
<b>Ranibizumab 0.5 mg</b>				
<b>(Group I; VA stabilization)</b>				
<b>(n = 182)</b>				
<b>Ranibizumab 0.5 mg</b>				
<b>(Group II; disease activity)</b>				
<b>(n = 182)</b>				
<b>vPDT</b>				
<b>(Group III)</b>				
<b>(n = 91)</b>				
	4.16 (9.47)	1.04 (1.38)	1.76 (2.22)	0.53 (0.58)
	3.00 (4.22)	0.84 (1.01)	1.83 (2.79)	0.54 (0.73)
	2.93 (3.98)	0.97 (1.96)	2.10 (2.71)	0.62 (0.67)

\*Consisted of all patients to whom study treatment were assigned.

SD, standard deviation; VA, visual acuity; vPDT, verteporfin photodynamic therapy